JUNE AND JOINING US NOW TO
DISCUSS THAT IS DOCTOR JONATHAN
JAB AT C E OF NARROW
OR ACTS AND ADJUNCT PROFESSOR
JOHN HOPKINS SCHOOL
OF MEDICINE. DOCTOR THANK YOU
SO MUCH FOR JOINING ME THIS
MORNING, 50 THE MILLION OF
THESE CHANGING DOSES AT JUST
DOWN THE DRAIN, HOW SOMETHING
LIKE THAT HAPPEN.
>> WELL I THINK WHAT YOU
POINTED OUT IS THAT YOU HAVE
TO PUT QUALITY FIRST IN EVERY
MANUFACTURING PROCESS,
ESPECIALLY PHARMACEUTICAL
MANUFACTURING PROCESSES AND IS
CERTAINLY KNOWN FOR DOING THAT
OVER A 100 YEARS OF
BEING DONE BUSINESS SOMETIMES
HUMANS WILL MAKE ERRORS THE
CRITICAL THING IS TO CATCH
THOSE AREAS WHERE THE ITS BUT
THAT SAID.
>> IS YOUR COMPANY OUT WORKING
IN THIS FIGHT AGAINST COVID AT
TO TRY TO LESSEN THE SITUATION
AT HAND.
>> WELL A YEAR
AGO WE WERE GIVEN THE CHANCE TO
TAKE ON A DRUG THAT REALLY
HADN'T BEEN USED IN THIS FORM
SINCE 2000 POT.
AND OVER THE COURSE
OF 12 MONTHS WE'VE BEEN ABLE TO
MOUNT
A CLINICAL TRIAL TO FORMULATE
THAT DRUG TO BRING THAT ROAD TO
THE PATIENTS, BUT SIDE
AND JUST THIS LAST WEEK TO
ANNOUNCE DATA SHOWING THAT
PEOPLE WHO GOT THIS
DRUG WAS STATISTICALLY
SIGNIFICANTLY CLINICALLY
SIGNIFICANTLY MORE
LIKELY TO COVER FROM COVID-19
RESPIRATORY FAILURE THAT'S WHAT
PUT YOU IN THE ICU ON A
VENTILATOR OR HIGH OXYGEN.
MORE LIKELY TO SURVIVE TO 60
DAYS TO GO HOME AND BE WITH
THAT.
>> RESEARCHING THAT FURTHER OR
ARE YOU PLANNING TO COME TO
MARKET WITH OTHER OPTIONS
TREATMENTS AS WELL.
>> WELL WE TOLD THE PUBLIC THAT
WE'RE APPLYING TO
THE FDA.
>> FOR EMERGENCY USE
AUTHORIZATION FOR THIS
INTRAVENOUS FORM
OF THAT AND WE'VE ALSO
ANNOUNCED THAT WE'RE STARTING A
TRIAL. WE'VE ALREADY STARTED
THE TRIAL WITH AN INHALED FORM
OF THE DRUG FOR PEOPLE WHO HAVE
EARLIER STAGES OF COVID WITH
THE HOPES THAT WILL KEEP THEM
OUT OF THE ICU.
>> I DO WANT TO TALK ABOUT ON
THIS RECENT PFIZER STUDY THAT
WE GOT IN CHILDREN WE SAW THIS
EARLIER THIS WEEK AS WE STILL
SEE COVID HEADLINES
UNFORTUNATELY, AS CASES DO TAKE
UP HERE IN THE UNITED STATES OF
THE PAST
FEW WEEKS. SO PFIZER FIND THE
NET ITS VACCINE. 90% EFFECTIVE
FOR AT LEAST 6 MONTHS.
THAT CERTAINLY IS A BENEFIT
WILL TALK ABOUT CHILDREN IN
JUST A SECOND HERE WHAT DOES
THAT SIGNAL TO YOU I MEAN I
THINK MANY PEOPLE WOULD HOPE
OKAY IT'S IT'S GOOD
NUMBERS, BUT WHY ISN'T IT 12
MONTHS OR 24 MONTHS.
JUST 6 MONTHS THAT WE GET THAT
90% EFFICACY WHAT'S YOUR VIEW.
>> THIS IS A VIRUS THAT'S A LOT
SMARTER THAN
WE THOUGHT IT TO BE JUST AS THE
FLU VIRUS MUTATES EVERY YEAR
AND IT'S HARD TO STAY AHEAD OF
THE FLU WITH NEWER IN ORDER
THAT SCENES. THIS VIRUS IS
CHANGING RAPIDLY SO THE BEST WE
CAN HOPE FOR IS
TO GET THIS VIRUS DOWN TO THE
LEVELS THAT WE TOLERATED WITH
THE FLOW BUT EVEN WITH
THOSE LEVELS, 50,000 AMERICANS
CAN DIE IN A
SINGLE YEAR, NO PLAYER. SO
THERE'S ALWAYS GOING TO BE A
NEED FOR COVID THERAPEUTICS NO
MATTER HOW GOOD THEIR VACCINES
YET.
>> AT PFIZER AND BIONTECH
SAYING THAT THIS VACCINE.
A 100% EFFECTIVE IN CHILDREN
AGES, 12 TO 15 YEARS CALLED HOW
CRITICAL IS THAT AGE GROUP
GETTING THEM VACCINATED SO THAT
THEY TOO ARE SAFE FROM THE CAR
CORONAVIRUS AND WE CAN GET
CLOSER TOWARD HERE HERD
IMMUNITY.
>> IT ISN'T SO MUCH A MATTER
CHILDREN BEING SAFE. BUT AS
THIS VIRUS DOESN'T AND
TO HARM SO THE CHALLENGE IS TO
HAVE CHILDREN BE IMMUNE.
SO THAT THEY'RE NOT BRINGING
THE VIRUS HOME TO VULNERABLE
ADULTS.
>> YOU KNOW THIS
STUDY ON THAT FINDING PFIZER'S
VACCINE DOES PROTECT AGAINST
THE SOUTH AFRICAN VARIANT OUT
THE ONE THAT SHOWED EARLIER
THIS WEEK THAT IT'S 90%
EFFECTIVE AT LEAST 6 MONTHS
LATER. THESE VARIANTS THE ONE
FROM SOUTH AFRICA, THE ONE FROM
THE UK, THE ONE FROM SOUTH
AMERICA SHOWING THAT THEY ARE
MORE HIGHLY CONTAGIOUS
AND THEN THE ORIGINAL STRAIN
WHICH IN AND OF ITSELF WAS
HIGHLY CONTAGIOUS. HOW CRITICAL
IS THIS.
>> WELL I THINK WHAT THIS IS
TEACHING US IS THAT THE
VARIANTS WILL CONTINUE TO TRY
TO GET AROUND
THE UNIONS. THAT'S WHAT VIRUSES
DO AND SO FAR THE VACCINE HAS
MANAGED TO DEFEAT MOST OF
THE VARIANCE BUT AS YOU SAY TO
THE 90% LEVEL THAT MEANS THAT
THERE ARE ALWAYS GOING TO BE
PEOPLE
AT RISK ALWAYS GOING TO BE
PEOPLE GETTING COVID THEY'LL BE
THE
MOST VULNERABLE WILL PEOPLE AND
THAT'S WHY WE NEED DRUGS THAT
CAN HELP KEEP THOSE PEOPLE OUT
OF
THE ICU OR GOD FORBID THEY GO
TO THE ICU GET THEM HOME SAFELY